Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many

Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many

Source: 
Endpoints
snippet: 

Just a few weeks after Rhythm Pharmaceuticals $RYTM snagged an FDA OK for setmelanotide in 3 rare genetic disorders that trigger obesity, the biotech is struggling to make a good case for a crucial market expansion.